부산대학교 도서관

Norovirus (NV) is a major cause of acute gastroenteritis worldwide.1,2 In solid organ transplant (SOT) recipients, NV can lead to serious complications such as dehydration, malnutrition, renal dysfunction, and death.1,2 Previous case reports have described the use of immunosuppression reduction and immunoglobulins for treatment of NV in SOT recipients.1-4 Nitazoxanide is an antiprotozoal that is considered to have broad antiviral activity.5 Case series and reports have been published describing the use of nitazoxanide for the treatment of NV in immunocompromised hosts, though results are variable.1-4 We conducted this study to evaluate the effectiveness of nitazoxanide in adult and pediatric SOT recipients with NV. METHODS This was an IRB-approved, single-center retrospective study of all SOT recipients with GI PCR positive for acute NV who either received nitazoxanide for NV or did not receive nitazoxanide between January, 2015 and August, 2019. Nitazoxanide is an ineffective treatment of chronic norovirus in patients with X-linked agammaglobulinemia and may yield false-negative polymerase chain reaction findings in stool specimens. [Extracted from the article]